GlassScriptPhysician profile
Lisa A Young
NPI 1235122748
$4,947.98
in general payments reported to CMS, 2019-2025
23 companies · $1,488 in 2025
The $1,488 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.66 · 2020: $51.99 · 2021: $623 · 2022: $619 · 2023: $524 · 2024: $1,561 · 2025: $1,488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,248 · Honoraria: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,247.58 |
| Honoraria | $325.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $984.55 | 2023-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Bausch & Lomb Americas INC. | $831.52 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Alcon Vision LLC | $691.54 | 2022-2025 | Rocklatan, Tryptyr, Simbrinza |
| Aerie Pharmaceuticals, INC. | $469.61 | 2021 | |
| Abbvie INC. | $429.52 | 2022-2025 | |
| Topcon Healthcare, INC. | $339.82 | 2025 | |
| Novartis Pharmaceuticals Corporation | $159.25 | 2019-2023 | |
| Amgen INC. | $152.84 | 2024-2025 | Tepezza |
| Allergan, INC. | $128.10 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $123.96 | 2020-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $123.30 | 2024 | Xdemvy |
| Thea Pharma INC. | $80.16 | 2024-2025 | Iyuzeh |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $67.84 | 2021 | |
| Mallinckrodt Hospital Products INC. | $62.94 | 2023-2025 | Acthar |
| Glaukos Corporation | $55.87 | 2024 | Idose |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tearlab Corp | $49.15 | 2022 | |
| Astellas Pharma US INC | $47.90 | 2024-2025 | Izervay |
| Harrow Eye, LLC | $45.09 | 2024 | Vevye |
| Apellis Pharmaceuticals, INC. | $33.12 | 2025 | Syfovre |
| Iridex Corporation | $22.17 | 2019 | |
| Sight Sciences, INC. | $20.04 | 2022 | |
| New World Medical,INC. | $16.85 | 2019 | |
| Eyevance Pharmaceuticals LLC | $12.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Young listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.